Figure 5.

Addition of PD-1 or TIM-3 Blocking Antibody Therapy to VSV-hgp100+ACT Therapy Minimally Alters Immune Kinetics

Mice from Figure 3B had serial submandibular vein blood samples taken at the time points indicated in (B)–(H). (A) Gating strategy shows representative plot to distinguish Pmel adoptively transferred Thy1.1⁺ from BL/6 endogenous Thy1.1⁻ cells, gated on CD8⁺ cells. (B and C) Frequencies of effector cells (CD44^hiCD62L^lo) gated on CD4⁺ or CD8⁺ cells. (D) Frequencies of PD-1⁺ TIM-3⁺ cells gated on CD8⁺ effectors. (E and F) Frequency and number of Thy1.1⁺ Pmel T cells gated on CD8⁺ cells. (G) Frequency of effector (CD44^hiCD62L^lo) cells gated on CD8⁺ Thy1.1⁺ cells. (H) Frequencies of PD-1⁺ TIM-3⁺ cells gated on CD8⁺ Thy1.1⁺ effectors. Each of the points represents 1–5 mice/group. The median with interquartile range is shown. *p < 0.05. The significance was determined at p < 0.05.